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We read with interest the paper by Miettinen et al. (1) demonstrating that the higher the absorption of 
cholesterol, the higher the plant sterol contents are in serum resulting in their higher contents in atherosclerotic 
plaque. The prospective Cardiovascular Munster (PROCAM) study found that people in the upper quartile of 
sitosterol levels had a 1.8-fold increased risk of major coronary events compared with those in the lower three 
quartiles (2). Statin treatment decreases cholesterol synthesis but increases absorption of plant sterols (3). In the 
Scandinavian Simvastatin Survival Study (4S), no reduction was observed in recurrence of coronary heart 
disease with the use of simvastatin in patients with high baseline plant sterol contents and with marked increase 
of serum plant sterols during the five-year treatment period (4). Additional treatment with inhibition of sterol 
absorption (e.g., with plant stanol esters) was suggested for this particular group of patients (3,4). To this respect, 
we were surprised that Miettinen et al. (1) did not consider the potential of combining ezetimibe with statin. 
Indeed, in addition to inhibiting intestinal cholesterol absorption, a well-known effect, ezetimibe also reduces 
plasma concentrations of the non-cholesterol sterols sitosterol and campesterol, suggesting an effect on the 
absorption of these compounds as well (5). It has been demonstrated recently that the Niemann-Pick C1-like 1 
(NPC1L1) transporter is most likely responsible for the transport of cholesterol and plant sterols from the brush 
border membrane into the intestinal mucosa (6). The intestinal absorption of plant sterols differs markedly from 
that of cholesterol and their biliary excretion as well. The presence of two specific ABCG5/ABCG8 transporters 
in the intestinal wall is responsible for rapid resecretion of plant sterols into the intestine lumen and thus rather 
low intestinal absorption of campesterol and sitosterol, and their presence in the liver explains why plant sterols 
are excreted much faster in the bile than cholesterol (7,8). Ezetimibe interferes with NPCILI, reducing the 
intestinal uptake of cholesterol and plant sterols (6-8). Interestingly, the reduction of plant sterol serum levels 
with ezetimibe was significantly more pronounced than the reduction of serum cholesterol (7,8). Clinical data on 
ezetimibe could demonstrate that the concept of inhibiting intestinal absorption of neutral sterols is beneficial in 
both patients with hypercholesterolemia as well in patients with hypersitosterolemia, an inherited disease with 
identified mutations in ABCG5/ABCG8 transporters that leads to a high prevalence of cardiovascular disease 
(9). Recent observations, such as those by Miettinen et al. (1), that elevated serum plant sterols pose an increased 
cardiovascular risk suggest that increases of serum plant sterol levels should be avoided, especially in 
atherosclerosis-prone individuals (1). Therefore, subjects with high cholesterol absorption and low synthesis may 
need a therapy combining statin and ezetimibe to lower more effectively their serum cholesterol levels and 
prevent an increase in the levels of plant sterols (3). The question remains, however, as to whether lowering 
serum levels of plant sterols (especially in high-absorber patients on statin therapy) with a drug such as ezetimibe 
will decrease the incidence of coronary artery disease. 
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REPLY 
Tatu A. Miettinen, MD, PhD ; Mikael Railo, MD, PhD ; Mauri Lepäntalo, MD, PhD ; Helena Gylling, MD, PhD 
In the letter by Drs. Radermecker and Scheen, it was noted that we have not commented the potential of 
combining ezetimibe to statins (1). The additional low-density lipoprotein (LDL) lowering of combining 
cholesterol absorption inhibitors to statins is relatively small, usually approximately 15%, for instance, for 
ezetimibe or plant stanols. No clinical studies have been published defining their additional reduction of 
coronary events during these treatments, which seems to be true also for their monotherapy, even though they are 
suitable for treatment of modestly increased LDL cholesterol, and stanol ester management also provides the 
heart-healthy fatty acids. Relatively low LDL cholesterol lowering either in mono- or in combination with statin 
treatment certainly requires randomized large-enough study populations treated for relatively long periods of 
time to record changes in heart events. In addition to LDL cholesterol lowering, cholesterol absorption inhibitors 
lower also plant sterol levels off or on statin treatment. Thus, they also normalize statin-induced increase of plant 
sterols. The endarter-ectomized patients treated with statin in our study had increased serum plant sterol ratios to 
cholesterol, which appeared also to be reflected in atheromatous plaques of carotid arteries (1). This finding 
certainly rises a question as to whether the lowering of serum plant sterols with cholesterol absorption inhibitors, 
e.g., ezetimibe or plant stanols, also could reduce plant sterol contents in the plaques. However, it also raises the 
question of whether an increase of serum plant sterols, e.g., during the consumption of plant sterol-enriched 
functional foods, also could enhance their concentrations in atheromatous plaques. Several studies have shown 
that increased serum plant sterols, even their ratios to cholesterol, are associated with enhanced coronary artery 
disease in crossover or follow-up investigations (2). However, in the Scandinavian Simvastatin Survival Study, 
no association was found in the control group between the five-year coronary events and baseline plant sterol 
concentrations or ratios to cholesterol (2). In the respective simvastatin treatment group, coronary events were 
reduced significantly in the low absorber but unchanged in the high absorbers, suggesting that additional 
lowering of LDL cholesterol is needed in the latter type of patients, e.g., by combination with cholesterol 
malabsorption. Statin treatment seems to improve endothelial function of carotid arteries despite increasing 
serum plant sterols (3); however, vascular function was unaffected with phytosterol-enriched food when LDL 
cholesterol was lowered and serum plant sterols were increased (4,5). Drs. Radermecker and Scheen concluded 
that "elevated serum plant sterols pose an increased cardiovascular risk," but clinical heart event reduction with 
their pharmacological lowering is still open. 
 
